Atea Pharmaceuticals (AVIR) Total Current Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 53.43% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 53.43% YoY), while the FY2025 annual figure was $39.8 million, up 113.86% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $33.4 million, down from $39.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $41.3 million in Q1 2024, with the low at $12.4 million in Q1 2023.
• The 5-year median for Total Current Liabilities is $21.7 million (2025), against an average of $24.4 million.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities slumped 94.03% in 2022, then surged 234.2% in 2024.
• Atea Pharmaceuticals' Total Current Liabilities stood at $18.5 million in 2022, then soared by 75.21% to $32.4 million in 2023, then slumped by 42.54% to $18.6 million in 2024, then soared by 113.86% to $39.8 million in 2025, then slipped by 16.13% to $33.4 million in 2026.
• Business Quant data shows AVIR's Total Current Liabilities at $33.4 million in Q1 2026, $39.8 million in Q4 2025, and $20.2 million in Q3 2025.